Looking for biological factors to predict the risk of active cytomegalovirus infection in non-immunosuppressed critically ill patients

Journal of Medical Virology

Volumn 86, Issue 5, 2014, Pages 827-833

  Bravo, Dayana ^a   Clari, María A ^a   Aguilar, Gerardo ^a   Belda, Javier ^a,b   Giménez, Estela ^a   Carbonell, José A ^a   Henao, Liliana ^a   Navarro, David ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Active CMV infection; CMV DNA load; Critically ill patients; Cytomegalovirus; Single nucleotide polymorphisms

Indexed keywords

BIOLOGICAL FACTOR; CHEMOKINE RECEPTOR CCR5; IMMUNOGLOBULIN G; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HOSPITAL ADMISSION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SALIVA LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TRACHEAL ASPIRATION PROCEDURE; VERY ELDERLY; VIRUS LOAD; VIRUS REACTIVATION; YOUNG ADULT;

CYTOMEGALOVIRUS;

ACTIVE CMV INFECTION; CMV DNA LOAD; CRITICALLY ILL PATIENTS; CYTOMEGALOVIRUS; SINGLE NUCLEOTIDE POLYMORPHISMS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CRITICAL ILLNESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE SUSCEPTIBILITY; DNA, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INTERLEUKIN-10; MALE; MIDDLE AGED; PLASMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR5; SALIVA; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84895924487     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23838     Document Type: Article

References (25)

1. Blanquer J, Chilet M, Benet I, Aguilar G, Muñoz-Cobo B, Tellez A, Costa E, Bravo D, Navarro D. 2011. Immunological insights into the pathogenesis of active CMV infection in non-immunosuppressed critically ill patients. J Med Virol 83:1966-1971.
2. Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, Allardet-Servent J, Gainnier M, Zandotti C, Papazian L. 2009. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 37:1850-1857.
3. Chiche L, Forel JM, Thomas G, Farnarier C, Cognet C, Guervilly C, Zandotti C, Vély F, Roch A, Vivier E, Papazian L. 2012. Interferon-γ production by natural killer cells and cytomegalovirus in critically ill patients. Crit Care Med 40:1-8.
4. Chilet M, Aguilar G, Benet I, Belda J, Tormo N, Carbonell JA, Clari MA, Costa E, Navarro D. 2010. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit. J Med Virol 82:1384-1391.
5. Clari MÁ, Bravo D, Costa E, Muñoz-Cobo B, Solano C, Remigia MJ, Giménez E, Benmarzouk-Hidalgo OJ, Pérez-Romero P, Navarro D. 2013a. Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn Microbiol Infect Dis 75:207-209.
6. Clari MA, Aguilar G, Benet I, Belda J, Giménez E, Bravo D, Carbonell J, Henao L, Navarro D. 2013b. Evaluation of Cytomegalovirus (CMV)-Specific T-Cell Immunity for the Assessment of the Risk of Active CMV Infection in Non-Immunosuppressed Surgical and Trauma Intensive Care Unit Patients. J Med Virol (In press).
7. COBAS®, TaqMan® CMV Test FDA approved package insert, July, 2012.
8. Cohen JI. 2009. Cytomegalovirus in the intensive care unit: Pathogen or passenger? Crit Care Med 37:2095-2096.
9. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. 2006. Lipopolysaccharide, Tumor Necrosis Factor Alpha, or Interleukin-1β triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 80:9151-9158.
10. Cook CH. 2007. Cytomegalovirus reactivation in "immunocompetent" patients: A call for scientific prophylaxis. J Infect Dis 196:1273-1275.
11. Correia-Silva JdeF, Victória JM, Guimarães AL, Salomão UE, de Abreu MH, Bittencourt H, Gomez RS. 2007. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients. Oral Dis 13:163-169.
12. Escribano A, Chilet M, Clari MA, Lucas R, Costa E, Bravo D, Muñoz-Cobo B, Borrás R, Navarro D. 2013. Frequent detection of cytomegalovirus (CMV) DNA in the lower respiratory tract in CMV-seropositive pediatric patients with underlying chronic bronchopulmonary diseases lacking canonical immunosuppression. J Med Virol 85:888-892.
13. Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ, Furió S, Calabuig M, Tormo N, Navarro D. 2008. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 46:3311-3318.
14. Griffiths PD. 2010. Cytomegalovirus in intensive care. Rev Med Virol 20:1-3.
15. Kalil AC, Florescu DF. 2009. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppresed patients in the intensive care unit. Crit Care Med 37:2350-2358.
16. Fryer JF, Heath AB, Anderson R, Minor PD. and the collaborative study group. Collaborative study to evaluate the proposed 1st WHO International Standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2010; WHO/BS/10.2138.
17. Limaye AP, Kirby KA, Rubenfels GD, Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M. 2008. Cytomegalovirus reactivation in critically immunocompetent patients. JAMA 300:413-422.
18. Loeffler J, Steffens M, Arlt EM, Toliat MR, Mezger M, Suk A, Wienker TF, Hebart H, Nürnberg P, Boeckh M, Ljungman P, Trenschel R, Einsele H. 2006. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol 44:1847-1850.
19. Lucht E, Brytting M, Bjerregaard L, Julander I, Linde A. 1998. Shedding of cytomegalovirus and herpesviruses 6, 7 and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. Clin Infect Dis 27:137-141.
20. Mezger M, Steffens M, Semmler C, Arlt EM, Zimmer M, Kristjanson GI, Wienker TF, Toliat MR, Kessler T, Einsele H, Loeffler J. 2008. Investigation of promoter variations in dendritic cell-specific ICAM3- grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem- cell transplantation. Clin Microbiol Infect 2008 14:228-234.
21. Osawa R, Singh N. 2009. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care 13:1-10.
22. Papazian L, Fraisse A, Garbe L, Papazian L, Fraisse A, Garbe L, Zandotti C, Thomas P, Saux P, Pierrin G, Gouin F. 1996. Cytomegalovirus: An unexpected cause of ventilator-associated pneumonia. Anesthesiology 84:280-287.
23. Reddehase MJ, Balthesen M, Rapp M, Jonjić S, Pavić I, Koszinowski UH. 1994. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185-193.
24. Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (GRAIL). ClinicalTrials.gov Identifier: NCT 01335932.
25. Tadagaki K, Tudor D, Gbahou F, Tschische P, Waldhoer M, Bomsel M, Jockers R, Kamal M. 2012. Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity. Blood 119:4908-4918.